Institutional Ownership of Abbott Laboratories Shows Mixed Trends in Latest 13F Filings

A review of the most recent 13F filings for the period ending March 31, 2026, indicates a nuanced shift in institutional sentiment toward Abbott Laboratories (ABT). Out of a sample of 60 recent filings, 25 funds maintained positions in the healthcare giant. While aggregate holdings across the analyzed group rose, the internal distribution shows a trend toward reduction for many individual managers. This highlights the complexity of interpreting 13F data, which only discloses long positions and excludes short bets or hedging strategies, meaning the long positions may not reflect a fund's total directional bias. Between December 31, 2025, and March 31, 2026, the aggregate share count held by the tracked funds increased by approximately 5.08%, rising from 52,811,680 to 55,496,224 shares—a net gain of 2,684,544 shares. However, the trend was not uniform across all managers. Fourteen funds decreased their positions, while only six increased theirs. Notable exits during this period included Baxter Bros Inc., Core Wealth Advisors LLC, Seascape Capital Management, and Carlton Hofferkamp & Jenks Wealth Management LLC. The overall increase in aggregate shares suggests a baseline of institutional support, but the high number of funds trimming positions may indicate a cautious outlook among a subset of hedge fund managers regarding the stock's near-term trajectory.